Form 4: MindMed CEO Robert Barrow Sells Shares to Cover Tax Obligations

MindMed CEO Robert Barrow sold 15,659 common shares on June 25, 2024, to satisfy withholding tax obligations related to vested restricted stock units.

Summary

• Robert Barrow, the CEO of Mind Medicine (MindMed) Inc., sold 15,659 common shares on June 25, 2024.
• The sale was executed to cover withholding tax obligations associated with the settlement of vested restricted stock units.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan adopted on June 15, 2022.
• The shares were sold at a weighted average price of $7.22, with individual sales ranging from $7.20 to $7.26.
• Following the transaction, Barrow directly owns 564,543 common shares.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover taxes) by the CEO, which is neither particularly positive nor negative for the company's outlook.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the executive's sentiment about the company's future prospects. These transactions are often pre-planned under 10b5-1 trading plans to avoid any appearance of insider trading.

Comparison to Industry Standards

• Executive compensation practices, including the use of restricted stock units and 10b5-1 trading plans, are common across publicly traded companies.
• Comparable companies in the biotechnology and pharmaceutical sectors, such as Compass Pathways and Atai Life Sciences, also utilize similar compensation structures for their executives.
• The sale of shares to cover tax obligations is a standard practice and does not deviate from industry norms.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial condition.

Key Dates